Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Theresa Aly"'
Autor:
Lisa Lemond, Theresa Aly, Nicholas D. Walter, Pamela L. Rice, Elizabeth F. Redente, Emily F. Kauvar, Kevin Wanebo, Edward D. Chan
Publikováno v:
American journal of respiratory cell and molecular biology. 44(5)
Inflammatory oncotaxis, the phenomenon in which mechanically injured tissues are predisposed to cancer metastases, has been reported for a number of tumor types, but not previously for histologically proven lung cancer. We review clinical and experim
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2370afd4888e774f61a1acd714697396
https://pubmed.ncbi.nlm.nih.gov/21177982
https://pubmed.ncbi.nlm.nih.gov/21177982
Autor:
Li, Zhang, Roberto, Gianani, Maki, Nakayama, Edwin, Liu, Masakazu, Kobayashi, Erin, Baschal, Liping, Yu, Sunanda, Babu, Abby, Dawson, Kelly, Johnson, Mohamed, Jahromi, Theresa, Aly, Pamela, Fain, Jennifer, Barker, Marian, Rewers, George S, Eisenbarth
Publikováno v:
Novartis Foundation symposium. 292
A wealth of data in animal models indicates that type 1A diabetes results from T cell-mediated specific destruction of islet beta cells. There is evidence for the NOD mouse model that insulin is the primary autoantigen and a specific insulin peptide
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a89f7c4d0dd48c6d954a3ae9bef5cddb
https://pubmed.ncbi.nlm.nih.gov/19203094
https://pubmed.ncbi.nlm.nih.gov/19203094
Autor:
Theresa Aly
Publikováno v:
American Journal of Therapeutics; Nov2005, Vol. 12 Issue 6, p481-490, 10p
Publikováno v:
Novartis Foundation Symposium 292; 2008, pi-ix, 9p
Publikováno v:
Novartis Foundation Symposium 292; 2008, p85-98, 14p
Autor:
Aly, Theresa, Devendra, Devasenan, Barker, Jennifer, Liu, Edwin, Yu, Liping, Eisenbarth, George S.
Publikováno v:
Diabetes Care; May2004, Vol. 27 Issue 5, p1205-1206, 2p, 1 Graph
Autor:
Gregory R. Bock, Jamie A. Goode
This book is a comprehensive and up-to-date account of where we stand in immunological strategies for preventing or treating type 1 diabetes (T1D). Brings together contributions from the leaders in the arena of clinical immunotherapy, not limited to
